Loading patent…
AssigneeAsgard Therapeutics AB
InventorsCarlos Filipe Ribeiro Lemos Pereira, Cristiana Ferreira Pires, Fábio Fiúza Rosa, Luis Filijpe Henriques Oliveira
Estimating the term…
The present disclosure relates to compositions for reprogramming cells into conventional dendritic cells (cDC), particularly into cDC type 2 (hereinafter referred to as“cDC2” or“CD11b-positive dendritic cells”), methods and uses thereof. The present disclosure relates to the development of methods for making conventional dendritic cells With antigen presenting capacity from differentiated, multipotent or pluripotent stem cells by introducing and expressing isolated/synthetic transcription factors. More particularly, the disclosure provides methods for obtaining conventional dendritic cells (cDC), particularly cDC type 2 or CD11b-positive dendritic cells, by direct cell reprogramming With the surprisingly use of combinations of specific transcription factors.
1-27. (canceled)
A construct or a vector encoding a combination of at least three transcription factors, wherein the combination of encoded transcription factors is selected from the group consisting of :
The method according to 37, wherein the transduction step further comprises transducing the cells with at least one vector selected from the group consisting of:
Dependencies are inferred from the claim text.